“The ARO-AAT Phase 1 study provides the first readout on pharmacologic activity for a therapeutic leveraging our proprietary Targeted RNAi Molecule, or TRiM™, platform. We have escalated above a dose that we believe achieves maximal activity, and all doses to date appear to be generally well-tolerated.”

– Chris Anzalone, Ph.D., President and CEO of Arrowhead

(Source: Wikimedia Commons)

For three months since March 28^th, 2018, Arrowhead Pharmaceuticals Inc (NYSE: ARWR) has gained 87.41%, becoming one of the most profitable stocks in pharmaceuticals industry. The success of ARO-ATT, an important project of ARWR, is the main reason for this growth. On June 18^th, Arrowhead announced that the company has finished enrollment of a Phase 1 clinical study of ARO-AAT, the second generation subcutaneously administered RNAi therapeutic being developed. If successful, ARO-AAT can provide an effective treatment for a genetic liver disease related to alpha-1 antitrypsin deficiency. 44 participants will participate in the Phase 1 clinical study of ARO-ATT and it is estimated that this Phase will be completed by the end of 2018. After the announcement, ARWR jumped up by 24% that day.

Alpha-1 Antitrypsin Deficiency is one of the reasons for liver problems and adult lung disease. Unfortunately, there has not been anyway to prevent or cure this type of diseases. According to alpha1.org, every year, there are about 19 million people in the US are Alpha-1 “carriers”, who has one normal alpha-1 gene along with one abnormal one. Moreover, Alpha-1 seems to be inherited from parents to their children.

On March 28^th, 2018, I Know First has issued a strong 3-month Buy prediction for Arrowhead Pharmaceuticals with the signal of 10.34 and the predictability of 0.39. Three month later, ARWR shot up to $13.22 (87.41% upside), in line with our forecast.

Current I Know First subscribers received this bullish ARWR forecast on March 28th, 2018.

To subscribe today click here.

How to interpret this diagram

Please note-for trading decisions use the most recent forecast. Get today’s forecast and Top stock picks.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), formerly Arrowhead Research Corporation, incorporated on February 13, 2001, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company’s preclinical pipeline of RNA interference (RNAi) therapeutics includes both subcutaneously administered liver-targeted candidates and extra-hepatic candidates. The Company’s pre-clinical-stage drug candidates include ARO-HBV, ARO-AAT, ARO-LPA, ARO-AMG1, ARO-F12 and ARO-HIF2. ARO-HBV is an RNAi therapeutic candidate for the treatment of chronic hepatitis B infection. ARO-HBV is designed to silence the production of all hepatitis B virus (HBV) gene products. ARO-AAT is a therapeutic candidate for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency (AATD). ARO-AAT is designed to knock down the Alpha-1 antitrypsin (AAT) gene transcript and reduce the hepatic production of the mutant AAT protein.

Disclaimer

Before making any trading decisions, consult the latest forecast as the algorithm updates predictions daily. You can use the algorithm for intra-day trading. The predictability tends to become stronger with forecasts over longer time-horizons such as the 1-month, 3-month and 1-year forecasts.